# US 12,110,334 B2 · Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,110,334 B2
- Document ID: US12110334B2
- Status: Granted
- Kind: B2
- Application number: 18/153,277
- Filed: 2023-01-11
- Published: 2023-10-19
- Granted: 2024-10-08
- Earliest claimed: 2016-09-29
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Stephen L. Nishimura; Jianlong Lou; James D. Marks; Jody L. Baron; Yifan Cheng; Shenping Wu; Anthony Cormier; Naoki Takasaka
- Web page: https://patentgrep.com/patent/US12110334B2

## CPC

- C07K 16/2839: {against the integrin superfamily}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 31/20: for DNA viruses
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/22: against growth factors {; against growth regulators}
- G01N 33/563: involving antibody fragments
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

New antibodies and methods of use are described.

## Claims

### Claim 1

An antibody that specifically binds to human αvβ8 and that comprises heavy chain complementarity determining regions (CDRs) SEQ ID NO:299, SEQ ID NO:301, and SEQ ID NO:303; and light chain CDRs SEQ ID NO:307, SEQ ID NO:309, and SEQ ID NO:311.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain variable region comprising SEQ ID NO: 297.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a light chain variable region comprising SEQ ID NO: 305.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain variable region comprising SEQ ID NO: 297 and a light chain variable region comprising SEQ ID NO: 305.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein the antibody is a single-chain variable fragment (scFv).

### Claim 6 (depends on 1)

The antibody of claim 1, wherein the antibody is an IgG.

### Claim 7 (depends on 1)

The antibody of claim 1, wherein the antibody is linked to a detectable label.

### Claim 8 (depends on 1)

A method of detecting the presence, absence, or quantity of human αvβ8 in a sample, the method comprising,
contacting the antibody of claim 1 to the sample, and
detecting or quantifying binding of the antibody to the sample.

### Claim 9 (depends on 8)

The method of claim 8, wherein the sample is a formalin-fixed sample.

### Claim 10 (depends on 9)

The method of claim 9, wherein the sample is a formalin-fixed paraffin-embedded (FFPE) sample.

### Claim 11 (depends on 9)

The method of claim 9, wherein the sample comprises fibroblasts, stellate cells, chondrocytes, activated macrophages, T cells, or B cells.

### Claim 12 (depends on 9)

The method of claim 9, wherein the sample is a tumor.